ClinicalTrials.gg
RecruitingNCT07201974Updated Mar 20, 2026

Virtual Reality for Post-Stroke Gait Rehabilitation

An interventional study of Virtual Reality Training in Stroke, sponsored by McGill University. Recruiting at 1 site in Canada. Open to participants aged 40 Years to 84 Years. Per ClinicalTrials.gov, last updated 2026-03-20.

Sponsored by McGill University · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
40 Years to 84 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Stroke by McGill University — 7 open to participants now, 7 under way, none of them phase 3. Stroke · McGill University.

Planned enrollment
8th of 15
40 · median 40
Started
2026
with 1 other
No phase
15 of 16
6 open now
Registered
15th of 16
by date

Among the 16 studies in Stroke by McGill University, this one is the 8th largest by planned enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2026, is one of 15 with no phase, and was the 15th registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

7 of the 16 studies in Stroke by McGill University are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 40 Years to 84 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Stroke by McGill University, or all of them as a file.
02

Study summary

The goal of this clinical trial is to: (1) implement and test the feasibility of a new VR-ODT intervention offered as part of usual therapy time of patients with a sub-acute stoke; (2) explore the acceptability of the intervention from the perspective of clinicians and patients and; (3) implement measures to optimize the uptake and sustainability of the intervention within the clinical setting.

Participants will engage in a personalized VR-ODT training for 4 weeks (2X 1hr/week) targeting six well-established community walking demands related to (1) walking speed and (2) distance; (3) postural transitions; (4) obstacle avoidance; (5) dual-task walking and; (6) a combination of demands 1-5. For each demand, patients will progress through levels of increasing difficulty according to personalized goals and success criteria.

Read the detailed description

The project involves the VR-ODT set-up and intervention aimed at improving community walking in stroke survivors, to be implemented and tested within the clinical setting. The set-up comprises of a VR headset (HTC Vive) and an ODT (Infinadeck- to our knowledge the only one in Canada) allowing users to walk at self-selected speed in any direction (360 degrees) in a virtual environment representing a shopping mall in Montreal and nearby streets. Stroke individuals with an altered walking capacity (speed: 0.3 - 0.95m/s) will be recruited from the JRH in- and outpatient programs for 12 consecutive months.

Feasibility (Obj. 1) will be examined using the following measures collated post intervention: number of eligible vs. referred patients and treating clinicians involved; patient and clinician characteristics; adherence to the intervention and adverse events. Perceived mental and physical demands (NASA Tax Load Index), sense of presence (Single- Item Presence Questionnaire) and cybersickness (Simulator Sickness Questionnaire) will also be assessed. Acceptability (Obj. 2) patients and clinicians will be assessed using a Technology Acceptance Model Questionnaire that includes questions related to perceived ease of use and usefulness, as well as with open-ended questions. To optimize uptake and sustainability (Obj. 3), two clinicians (1 occupationnel therapist \& 1 physiotherapist) from the JRH stroke program will be trained as clinician-champions (CC) on using the VR-ODT intervention and supporting other clinicians with intervention delivery. The CC, in collaboration with the team, will generate instructional materials (written and video) that detail the intervention, targeted users and step-by-step procedures for clinical use. The CC will also be involved in demonstrations (X2) on the use of the intervention for clinicians. They will be the resource for any question or required assistance with the VR-ODT set-up \& intervention.

03

Conditions studied

  • Stroke

Browse trials for

Keywords

  • Rehabilitation
  • Intervention
  • Community Walking
  • Virtual Reality
  • Clinical care
04

Who can participate

Ages eligible
40 Years to 84 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Eligible patients with stroke referred by clinicians of the inpatient and outpatient stroke rehabilitation programs at the Jewish Rehabilitation Hospital (CISSS Laval) for mobility problems over a period of 6 months will be recruited. They will:

  • be aged between 40 and 74 years;
  • have normal/corrected visual and auditory acuity present;
  • present a first-ever supratentorial unilateral stroke of 1-24 weeks duration;
  • present the ability to walk independently with/without walking aids for at least 1 min at a speed of 0.4-0.9 m/s;
  • present intact or mildly affected cognitive function ( scores ≥ 22/30);
  • present intact to moderately affected visual- perceptual function (positive scores on a max. of 3/6 tasks on the Behavioural Inattention Test).

Exclusion criteria

Exclusion Criteria:

  • Subjects with comorbidities interfering with walking
  • Subjects with comorbidities interfering with visual perception
  • Subjects without medical clearance for exercise
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    VR training

    Participants will engage in a 4-week VR intervention that comprises of 1-hour training sessions, 2 times/week.

    Other: Virtual Reality Training

Interventions

  • OtherVirtual Reality Training

    The VR intervention involves the intensive practice of community ambulation skills. The training sessions will be performed in a virtual environment. During the intervention, stroke participants will be invited to practice different dimensions of community ambulation, such as postural transitions, avoiding other pedestrians, dual-task walking, etc.

06

What researchers measure

Primary outcomes

  1. Feasibility: adherence to intervention - number of completed sessions

    Training logbook filled by clinicians

    Time frame: 2x/week over the 4-week intervention

  2. Feasibility: presence of adverse or undesirable effects during the intervention

    Assesses by systematically collecting any occurrence of adverse/unwanted events (falls, injuries, fatigue, etc). Collected with open-ended questions.

    Time frame: Post-Intervention (week4)

  3. Feasibility: Number of participants recruited in each program

    Number of early discharged participants vs. outpatient program participants

    Time frame: Pre-intervention (week0)

  4. Feasibility: Characteristics of stroke participants: age

    Collected via medical charts

    Time frame: Pre-intervention (week 0)

  5. Feasibility: Characteristics of stroke participants: sex

    Collected via medical charts

    Time frame: Pre-intervention (week 0)

  6. Feasibility: Characteristics of stroke participants: gender

    Collected via medical charts

    Time frame: Pre-intervention (week 0)

  7. Feasibility: Characteristics of stroke participants: walking capacity

    Collected via medical charts. According to physiotherapy evaluations, walking capacity is characterized as severely, moderately or mildly affected.

    Time frame: Pre-intervention (week 0)

  8. Feasibility: Characteristics of stroke participants: cognitive function

    Collected via medical charts. According to occupationnal therapy evaluations, cognitive fonction is characterised as severely affected, moderately affected, mildly affected, or intact.

    Time frame: Pre-intervention (week 0)

  9. Feasibility: Characteristics of stroke participants: visual-perceptual function

    Collected via medical charts. According to occupationnal therapy evaluations, visual-perceptual function is characterised as severely affected, moderately affected, mildly affected, or intact.

    Time frame: Pre-intervention (week 0)

  10. Feasibility: Characteristics of clinicians

    collected via paper-based questionnaire

    Time frame: Pre-intervention (week0)

  11. Feasibility: Number of eligible vs. referred participants

    Assessed using the number of participants referred to the study in comparison to the list of admitted patients in the targeted stroke programs.

    Time frame: Post-intervention (week4)

  12. Feasibility: Perceived mental and physical demands

    Collected using the NASA Tax Load Index. It assesses work load on five 7-point scales. Increments of high, medium and low estimates for each point result in 21 gradations on the scales.

    Time frame: Post-Intervention (week4)

  13. Feasibility: Sense of presence

    Collected with the Single-Item Presence Questionnaire, a brief measure used to assess a participant's sense of presence in a virtual environment. It consists of one question rated on a 7-point Likert scale, ranging from 1 ("not at all") to 7 ("completely").

    Time frame: Post-Intervention (week4)

  14. Feasibility: Presence of cybersickness

    Collected via the Simulator Sickness Questionnaire, used for assessing symptoms of motion or simulator sickness following exposure to virtual environments. It includes 16 symptoms rated on a 4-point scale from 0 ("none") to 3 ("severe"), covering nausea, oculomotor discomfort, and disorientation.

    Time frame: Post-Intervention (week4)

  15. Acceptability of the intervention

    Assesses using the Technology Acceptance Model based Questionnaire (Tam-Q) based on the technology acceptance model, in which participants (patients and cliniciens) will rate their perception on each dimension using a visual analog scale ranging from 0-56, with higher score representing higher acceptance to the intervention.

    Time frame: Post-intervention (Week4)

  16. Acceptability: Overall experience

    Investigated through open-ended questions

    Time frame: Post-Intervention (Week4)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data for all primary and secondary outcome measure will be made available.

Time frame: Data will be available within 6 months of study completion

Access criteria: De-identified data will be deposited in a REDCap database and made available to collaborators. Data may also be made available to other researchers via an institutional data repository that will allow adhering to FAIR principles.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Nov 2026, 9 months after the start.

Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 9 months is below that.

Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2025
First posted
Oct 1, 2025
StartActual
Feb 1, 2026
Primary completionEst.
Nov 2026
CompletionEst.
Dec 2027
Last update
Mar 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07201974
Lead sponsor
McGill University
Collaborators
Jewish Rehabilitation Hospital
Responsible party
Anouk Lamontagne (Associate Professor, McGill University) — Principal investigator
First posted
Oct 1, 2025
Start date
Feb 1, 2026
Primary completion
Nov 2026 (estimated)
Completion
Dec 2027 (estimated)
Last update
Mar 20, 2026

Study contacts

Anouk Lamontagne, PhD
Contact
anouk.lamontagne@mcgill.ca
450-688-9550 ext. 84168
Myriamn Villeneuve, Mec
Contact
myriam.villeneuve@mail.mcgill.ca
514-216-1295
Anouk Lamontagne, PhD
principal investigator · McGill University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion